Elevated Alzheimer's Biomarker Detected in Newborns: A Closer Look at Phosphorylated Tau
New research reveals that newborns naturally have high levels of a key Alzheimer's biomarker, p-tau217, which may play a crucial role in brain development and offer insights for future Alzheimer's treatments.
Recent research has uncovered that newborn babies exhibit higher levels of a biomarker associated with Alzheimer's disease, called phosphorylated tau (p-tau217). This discovery was made through a comprehensive international study involving researchers from Sweden, Spain, and Australia, analyzing blood samples from over 400 individuals including healthy newborns, premature infants, young adults, and Alzheimer's patients.
The study revealed that newborns, especially premature ones, possess the highest plasma levels of p-tau217, which gradually decrease within the first few months of life to reach levels comparable to adults. Interestingly, in Alzheimer’s disease, elevated p-tau217 levels are linked to pathological tau aggregation that leads to neurofibrillary tangles and cognitive decline. Conversely, in newborns, the increase appears to play a role in healthy brain development, aiding in neuron growth and the formation of neural connections.
The research further indicates that in early life, p-tau217 levels are closely related to the timing of birth, with more premature infants showing higher levels. This challenges previous assumptions and suggests that tau phosphorylation might have a protective or developmental function during early brain maturation.
Scientists believe understanding how the healthy brain manages tau protein could inform new therapeutic approaches for Alzheimer’s. The dual role of p-tau217 underscores its importance: while it signals disease progression in older individuals, it might be a vital factor in normal brain development in infants. Plasma p-tau217 has recently gained FDA approval as a diagnostic tool for Alzheimer’s, but the new findings highlight the necessity to interpret its levels within a broader developmental context.
These insights open potential pathways to designing treatments that could leverage the brain's natural protective mechanisms against tau pathology, potentially slowing or halting the progression of Alzheimer’s disease. Further research aims to decipher why tau regulation deteriorates with age and how this knowledge can shape future interventions.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Monoclonal Antibody Treatment Significantly Reduces Hospitalizations in Infants with Bronchiolitis
A groundbreaking study reveals that a single dose of the monoclonal antibody nirsevimab can reduce bronchiolitis hospitalizations in infants under six months by nearly half, highlighting a new preventive approach against RSV infections.
'Clear' E-Cigarettes Cause Greater Immediate Increases in Blood Pressure and Heart Rate
New research highlights the cardiovascular risks associated with 'clear' e-cigarettes containing synthetic cooling agents. These products cause significant immediate increases in blood pressure and heart rate, posing health concerns amid ongoing regulation debates.
FDA Approves Vizz Eye Drops to Enhance Near Vision in Adults
The FDA has approved Vizz eye drops, a novel treatment for presbyopia, to improve near vision in adults by enhancing depth of focus without adverse effects. This innovative eye drop could transform presbyopia management.
Study Uses AI to Uncover Disparities in Amputation Rates Among Rural and Minoritized Populations
A new study employing AI uncovers the role of implicit bias in disparities of limb amputation rates among rural and minoritized populations with vascular disease, highlighting the need for equitable treatment guidelines.